Abstract
The last decades have witnessed an explosion in studies of the role of amyloid-β (Aβ) in the progress of the neurodegenerative disorder Alzheimer´s disease (AD) and it is now widely accepted that Aβ is related to the pathogenesis of AD. For example, studies have shown that Aβ is neurotoxic and that the neurotoxicity of Aβ is related to its aggregation state. The concentration of the 42 amino acid form of Aβ (Aβ1-42) is reduced in the cerebrospinal fluid (CSF) from AD patients, which is believed to reflect the AD pathology with plaques in the brain acting as sinks. Less well investigated, however, is the ability of other Aβ isoforms to distinguish AD patients from controls and to identify treatment effects in clinical trials. Recently, novel C-truncated forms of Aβ (Aβ1-14, Aβ1-15, and Aβ1-16) were identified in human CSF. The presence of these small peptides is consistent with a catabolic amyloid precursor protein cleavage pathway by β- followed by α-secretase. It has been shown that Aβ1-14, Aβ1-15, and Aβ1-16 increase dose-dependently in response to γ-secretase inhibitor treatment while Aβ1-42 levels are unchanged. Here, we review the many aspects of Aβ and its isoforms with special focus on their potential role as diagnostic and theragnostic markers.
Keywords: Alzheimer's disease, Amyloid, APP, biomarker, theragnostic marker, Abeta-degrading enzymes, Down's syndrome, mass spectrometry, amino acid, Western blot, Subventricular Zone (SVZ) Derived Oligodendrogenesis, Activated Astrocytes and Microglia, Remyelination, Molecular Therapies, Adult Neural Stem/Progenitor Cells (NPCs), Adult Mesenchymal Stem Cells (MSCs), Cell Transplantation, Immunemodulation, T and B Cells, Lymph Nodes, Blood Brain Barrier (BBB), Neuroprotection, Regeneration, Therapeutic Plasticity
Current Pharmaceutical Design
Title: Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Volume: 17 Issue: 25
Author(s): Erik Portelius, Niklas Mattsson, Ulf Andreasson, Kaj Blennow and Henrik Zetterberg
Affiliation:
Keywords: Alzheimer's disease, Amyloid, APP, biomarker, theragnostic marker, Abeta-degrading enzymes, Down's syndrome, mass spectrometry, amino acid, Western blot, Subventricular Zone (SVZ) Derived Oligodendrogenesis, Activated Astrocytes and Microglia, Remyelination, Molecular Therapies, Adult Neural Stem/Progenitor Cells (NPCs), Adult Mesenchymal Stem Cells (MSCs), Cell Transplantation, Immunemodulation, T and B Cells, Lymph Nodes, Blood Brain Barrier (BBB), Neuroprotection, Regeneration, Therapeutic Plasticity
Abstract: The last decades have witnessed an explosion in studies of the role of amyloid-β (Aβ) in the progress of the neurodegenerative disorder Alzheimer´s disease (AD) and it is now widely accepted that Aβ is related to the pathogenesis of AD. For example, studies have shown that Aβ is neurotoxic and that the neurotoxicity of Aβ is related to its aggregation state. The concentration of the 42 amino acid form of Aβ (Aβ1-42) is reduced in the cerebrospinal fluid (CSF) from AD patients, which is believed to reflect the AD pathology with plaques in the brain acting as sinks. Less well investigated, however, is the ability of other Aβ isoforms to distinguish AD patients from controls and to identify treatment effects in clinical trials. Recently, novel C-truncated forms of Aβ (Aβ1-14, Aβ1-15, and Aβ1-16) were identified in human CSF. The presence of these small peptides is consistent with a catabolic amyloid precursor protein cleavage pathway by β- followed by α-secretase. It has been shown that Aβ1-14, Aβ1-15, and Aβ1-16 increase dose-dependently in response to γ-secretase inhibitor treatment while Aβ1-42 levels are unchanged. Here, we review the many aspects of Aβ and its isoforms with special focus on their potential role as diagnostic and theragnostic markers.
Export Options
About this article
Cite this article as:
Portelius Erik, Mattsson Niklas, Andreasson Ulf, Blennow Kaj and Zetterberg Henrik, Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment, Current Pharmaceutical Design 2011; 17 (25) . https://dx.doi.org/10.2174/138161211797416039
DOI https://dx.doi.org/10.2174/138161211797416039 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Problem of Amino Acid Complementarity and Antisense Peptides
Current Protein & Peptide Science Molecular Biology of the Enzymes that Degrade Endocannabinoids
Current Drug Targets - CNS & Neurological Disorders Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Current Drug Targets Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies
Current Pharmaceutical Design Antiangiogenic Function of Antithrombin is Dependent on its Conformational Variation: Implication for Other Serpins
Protein & Peptide Letters Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Ion Channels as Important Targets for Antiepileptic Drug Design
Current Drug Targets A Combined Approach Using Patch-Clamp Study and Computer Simulation Study for Understanding Long QT Syndrome and TdP in Women
Current Cardiology Reviews Conformational Changes of Prion Protein and Nucleic Acid Arising from their Interaction and Relation of the Altered Structures in Causing Prion Disease
Mini-Reviews in Medicinal Chemistry Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Evaluation of Anticancer, Antibacterial and Antioxidant Properties of a Medicinally Treasured Fern Tectaria coadunata with its Phytoconstituents Analysis by HR-LCMS
Anti-Cancer Agents in Medicinal Chemistry Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets
CNS & Neurological Disorders - Drug Targets P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Current Drug Targets